Why the election is not as relevant to drug stocks as you might believe

' in='in' order='order' to='to' promote='promote' competition='competition' under='under' this='this' part='part' and='and' carrying='carrying' out='out' part,='part,' the='the' secretary='secretary' (of='(of' health='health' human='human' services):='services):' (1)='(1)' may='may' not='not' interfere='interfere' with='with' negotiations='negotiations' between='between' drug='drug' manufacturers='manufacturers' pharmacies='pharmacies' pdp='pdp' sponsors;='sponsors;' (2)='(2)' require='require' a='a' particular='particular' formulary='formulary' or='or' institute='institute' price='price' structure='structure' for='for' reimbursement='reimbursement' of='of' covered='covered' d='d'>

/www.streetwisereports.com/pub/co/4503" style="box-sizing: inherit; color: rgb(51, 51, 51); line-height: inherit; text-decoration: none;" target="_blank">"The recent weakness in pharmaceutical stocks affords an excellent buying opportunity in select names with promising pipelines, includingDURECT Corp."

This is in no way intended to justify the high cost of prescription pharmaceuticals. As I have previously written, I maintain that there are more appropriate methods to control these costs. Additionally, it is critical to understand that the drug spend represents only 12% of total U.S. healthcare dollars. I forecast healthcare costs to grow at an average annual rate of 6% through 2030, at which time they will exceed $7 trillion, or 25% of GDP. I have provided a means of bending the cost curve in my article, ' <>Solving America's Health Care Crisis."

/www.streetwisereports.com/pub/co/4348" style="box-sizing: inherit; color: rgb(145, 0, 36); line-height: inherit; text-decoration: none; font-weight: bold;" target="_blank">Merck & Co. Inc. (MRK:NYSE), Celgene Corp. (CELG:NASDAQ), Regeneron Pharmaceuticals Inc. (REGN:NASDAQ), Tesaro Inc. (TSRO:NASDAQ), Ardelyx Inc. (ARDX:NASDAQ)and DURECT Corp. (DRRX:NASDAQ).

/www.streetwisereports.com/pub/htdocs/signupnow.html" style="box-sizing: inherit; color: rgb(145, 0, 36); line-height: inherit; text-decoration: none; font-weight: bold;" target="_blank">Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their families are prohibited from making purchases and/or sales of those securities in the open market or otherwise during the up-to-four-week interval from the time of the interview/article until after it publishes.